ClinicalTrials.gg
RecruitingNCT07460856CRANOSUpdated Mar 10, 2026

Effects of Cranberry on Gut and Metabolic Health

An interventional study of Cranberry beverage and Placebo beverage in Overweight/Obesity, Metabolic Syndrome and Insulin Resistance, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Laval University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2025, registered Jan 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Obesity by Laval University — 11 open to participants now, 12 under way, none of them phase 3. Obesity · Laval University.

Planned enrollment
14th of 24
73 · median 94
Started
2025
with 2 others
No phase
19 of 31
7 open now
Primary completion
2026-12
later than 6 of 11 live
Registered
30th of 31
by date

Among the 31 studies in Obesity by Laval University, this one is the 14th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 30th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 31 studies in Obesity by Laval University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 25 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Obesity by Laval University, or all of them as a file.
02

Study summary

The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.

The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.

This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.

03

Conditions studied

  • Overweight/Obesity
  • Metabolic Syndrome
  • Insulin Resistance
  • Microbiota

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 73 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 25 and 40 kg/m2
  • at least one of the following criteria: fasting plasma insulin >60 pmol/L, fasting glycemia between 5.5 and 6.9 mmol/L, (HbA1c) level of 5.7- 6.4% and/or fasting triglyceride >1.35 mmol/L.

Exclusion criteria

Exclusion Criteria:

  • to have aversion to cranberry products
  • regularly drinking alcohol (>2 glasses/day)
  • having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions
  • taking medication which may affect the study outcomes (i.e. antidiabetic and/or cholesterol or lipid-lowering medications and/or glucocorticosteroid in supraphysiological doses and/or anti-obesity medications)
  • taking regular probiotics and prebiotics (including fruit/berry polyphenol supplements) in the past 3 months
  • having eating disorders
  • had undergone major surgery 3 months prior to the study or if they had one planned
  • if they had intestinal malabsorption, cirrhosis or chronic kidney disease
  • being pregnant, planning a pregnancy, or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (estimated)

Study arms

  • Experimental
    Cranberry beverage

    Dietary Supplement: Cranberry beverage

  • Placebo comparator
    Placebo beverage

    Dietary Supplement: Placebo beverage

Interventions

  • Dietary supplementCranberry beverage

    Daily consumption of 240 ml of cranberry beverage for 12 weeks.

  • Dietary supplementPlacebo beverage

    Daily consumption of 240 ml of placebo beverage for 12 weeks.

07

What researchers measure

Primary outcomes

  1. Change in glucose homeostasis

    Assessment of glucose concentrations during a 3-hour oral glucose tolerance test (OGTT)

    Time frame: Pre and post each treatment (12 week/each)

  2. Change in insulin secretion

    Assessment of insulin a concentrations during a 3-hour oral glucose tolerance test (OGTT)

    Time frame: Pre and post each treatment (12 week/each)

  3. Change in insulin secretion

    Assessment of C-Peptide concentrations during a 3-hour oral glucose tolerance test (OGTT)

    Time frame: Pre and post each treatment (12 week/each)

  4. Change in lipid profile

    Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol

    Time frame: Pre and post each treatment (12 week/each)

Secondary outcomes

  1. Change in other measures of glucose homeostasis

    Assessment of glycated hemoglobin (HbA1c)

    Time frame: Pre and post each treatment (12 week/each)

  2. Change in blood pressure

    Assessment of systolic and diastolic blood pressure

    Time frame: Pre and post each treatment (12 week/each)

  3. Change in chronic inflammation

    Assessment of plasma high sensitive C-Reactive Protein (hs-CRP) concentrations

    Time frame: Pre and post each treatment (12 week/each)

  4. Change in anthropometric measurements

    Assessment of body mass index (BMI) using weight and height. These two measurements will be combined to calculate BMI in kg/m2

    Time frame: Pre and post each treatment (12 week/each)

  5. Change in anthropometric measurements

    Assessment of waist circumference

    Time frame: Pre and post each treatment (12 week/each)

  6. Change in body composition

    Assessment of changes in lean mass, fat mass and visceral fat mass (all in grams) using body composition by Dual X-ray Absorptiometry scan

    Time frame: Pre and post each treatment (12 week/each)

  7. Change in gut microbiota

    Assessment of global variation of the fecal microbiota

    Time frame: Pre and post each treatment (12 week/each)

  8. Change in gut microbiota function

    Assessment of short-chain fatty acid (SCFA) in feces

    Time frame: Pre and post each treatment (12 week/each)

  9. Change in fat accumulation in the liver

    Evaluation of fat accumulation using magnetic resonance imaging (MRI) in a subgroup of women only.

    Time frame: Pre and post each treatment (12 week/each)

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 17 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Mar 10, 2026
StartActual
Jul 7, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07460856
Lead sponsor
Laval University
Collaborators
Ocean Spray Cranberries, Inc.
Responsible party
André Marette (Professor, Laval University) — Principal investigator
First posted
Mar 10, 2026
Start date
Jul 7, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Julie Marois, M.Sc.
Contact
julie.marois@fsaa.ulaval.ca
1-418-656-5258

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion